2026-06-02T12:27:50Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/289292026-02-03T11:24:17Zcom_10630_2254col_10630_37953

Palacios-Muñoz, María Rosario Mayorga, María Luisa González-Doménech, Carmen María Hidalgo Tenorio, Carmen Gálvez, Carmen Muñoz Medina, Leopoldo de la Torre, Javier Lozano, Ana Castaño, Manuel Omar, Mohamed Santos-González, Jesús Leandro 2024-01-19T11:04:30Z 2024-01-19T11:04:30Z 2018-01 Palacios R, Mayorga M, González-Domenech CM, Hidalgo-Tenorio C, Gálvez C, Muñoz-Medina L, de la Torre J, Lozano A, Castaño M, Omar M, Santos J. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study. J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325958218760847. doi: 10.1177/2325958218760847. https://hdl.handle.net/10630/28929 10.1177/2325958218760847 Objectives: To analyze the efficacy and safety of dolutegravir/rilpivirine (DTG/RPV) in HIV-infected patients who switched from any other antiretroviral therapy (ART). Methods: Open-label, multicenter study including patients who switched to DTG/RPV between February 2015 and February 2016. Efficacy (HIV RNA <50 copies/mL), adverse events, and metabolic changes at 24 weeks were analyzed. Results: A total of 104 participants were included, who switched for the following reasons: toxicity/intolerance (42.3%), convenience (27.8%), and drug interactions (17.3%). Prior regimens are protease inhibitor (56.7%), integrase strand transfer inhibitor (26.9%), and non-nucleoside reverse transcriptase inhibitor (16.3%). Efficacy at 24 weeks was 88.4% (intention to treat) and 96.8% (per protocol). Triglyceride levels were reduced, on average, by 12.7% and a mean decrease of 9.0% in the glomerular filtration rate was observed as well ( P values of .003 and .002, respectively), whereas total cholesterol, HDL cholesterol, LDL cholesterol, creatinine, and glutamic-pyruvic transaminase remained unchanged. No patient discontinued due to adverse events. Conclusions: Dolutegravir/RPV is effective and safe in long-term HIV-infected patients under any prior ART. Toxicity, convenience, and interactions were the main reasons for changing. At 24 weeks, the lipid profile improved with a decrease in triglycerides. eng open access Infecciones por VIH Safety and efficacy of dolutegravir plus rilpivirine in treatment-experienced HIV-Infected Patients: the DORIVIR study journal article